Who is BioStrand?
We are a Belgian BioTech start-up from Hasselt making revolutionary technology for multi-OMICs data analysis.
We, at BioStrand, are on a mission to make omics analysis effective and available for every researcher.
Stream data to create and apply knowledge will revolutionise life sciences.
Today, genomic data analysis is a complex series of operations. Often only specially trained professionals are able to perform these analyses. Costly subscriptions to compute and store these genomic data are needed. Furthermore, omics data reside mostly in silos and integrating these omics data and meta data are difficult.
To make fundamental progress in life sciences, precision medicine, agriculture and food tech, these problems will have to be tackled first. We, at BioStrand, can solve these problems.
We have created a platform that makes all omics data and meta data actionable and allows analysis by everyone involved in omics research.
Our goal is to provide technology that can revolutionise genetic research being done in R&D departments at pharmaceutical, biotechnology, diagnostic, agrochemical and food technology companies.
Contact us today to set up a meeting with one of our experts or request a demo.
Our Innovative Technology
BioStrand offers a revolutionary methodology for identifying similarities and variations in genetic data and detecting structural anchor points that will drive innovation.
BioStrand is the first company since the 1980s to come up with a completely new, out-of-the-box solution for omics data analysis. Where next generation sequencing revolutionised sequence data generation in the last decade, BioStrand now revolutionises sequence data analysis.
The BioStrand methodology enables unprecedented accuracy and speed of operation in detecting similarities and variations in DNA, RNA and proteins. By detecting HYFTSTM, structural 3D information is automatically integrated into the analyses, revolutionising pattern and profile detection that are critical in understanding diseases and biological processes.
With our fundamentally new method we make sure that omics data analysis finally can keep pace with data generation.
We unlock the true potential present in omics data and close the gaps towards precision medicine. Just in time.
BioStrand was born from the recognition that omics analysis needed significant improvements.
Founded by a family team with decades of experience in medical research and healthcare, bioIT, big data and NLP, we spent seven years conducting private research about genetic analysis technology and its major barriers, and the potential opportunities. Inspired by cross-domain knowledge stemming from text analytics to evolutionary biology, we developed the formulation of hypotheses, designed algorithms to test them and further expanded our initial ideas. Step by step the project grew until we had a working prototype.
March 29, 2022
January 1, 2022
We received a €460,000 round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship) for the second time.
August 1, 2021
We released R&R 1.0 as well as the BioStrand data analysis and management platform. Publication of the white paper with the results on the Hasselt University validation study of the R&R algorithm.
July 1, 2021
We have grown to a team of 15
November 1, 2020
We released the beta version of R&R
June 1, 2020
We welcomed our first data scientists/engineers. We received a 235 K Euros Innovation Grant from the Flemish Government
May 15, 2020
We raised 2 M Euros in a seed round. K&E, the Holding behind Globachem invested
April 1, 2020
MVP for first platform finalised
February 6, 2019
We founded the company and filed a patent
Upcoming milestones: Variation analysis to be launched. Extensive NLP possibilities, prediction of 3D protein structure and protein-protein interaction
Our Culture and Values
Outside-the-box thinking is our natural attitude. Innovative ideas arise from creative thinking and fast failure.
Do what you say and say what you do. Achieving great things is only possible when working together in a relationship based on mutual trust and respect.
We operate in a cross-domain environment. Great achievements are always the result of teamwork. The whole is greater than the sum of its parts.
We are not only colleagues, we are the BioStrand family. Working hard also means having fun and caring for each other.
April 14, 2022
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue
VICTORIA, BRITISH COLUMBIA (CANADA), April 14, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over..
Protein structure prediction: On the route from sequence to function
As discussed in our previous blog post in this series, there is a large discrepancy between sequenced proteins and structure-resolved proteins. This..
Scaling up structural biology with AlphaFold2
The unveiling of AlphaFold2 during the Critical Assessment of Structure Prediction (CASP) 14th edition has been a turning point in the field of..
Data-Driven Biomedical Research
Data-driven biomedical research is the foundation of effective precision medicine (PM). Of course, over the long term, the success of the PM model..
"Healthy scepticism is the basis of all accurate observation."
- Arthur Conan Doyle